Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency. (2016)
Attributed to:
Development of a novel, potent, safe, long-lasting lentivirus-based gene therapy for cystic fibrosis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Publication URI: http://online.liebertpub.com/doi/pdfplus/10.1089/hum.2016.29027.abstracts
Type: Conference/Paper/Proceeding/Abstract
Volume: 27
Issue: 7